At 2 years, Black and white patients who received Lucentis for the treatment of diabetic macular edema achieved similar ...

Children with albinism and visual impairment demonstrate better visual search performance than other children with other visual impairments.

The eyes are a window to the brain – and this outward extension of the central nervous system may reveal early signs of ...

The company describes KSI-101 as a “novel, potent, and high-strength (100 mg/mL) antibody-based investigational therapy with ...

If untreated, a disorder of high brain pressure called idiopathic intracranial hypertension can lead to vision loss. But this ...

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today follow-up ...

D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all ...

MCO-010, an optogenetic therapy, demonstrated long-term safety and improved quality of life in patients with retinitis ...

83% (78/94) of patients demonstrated ocular tumor shrinkage, with 54% (51/94) achieving ≥20% tumor shrinkage 57% (24/42) eye preservation rate in enucleation (EN) recommended patients, which increased ...

If untreated, a disorder of high brain pressure called idiopathic intracranial hypertension can lead to vision loss. But this disorder can develop without noticeable symptoms, making it hard to catch.

At what point does the resolution on a TV display outpace what human eyes can actually see? Researchers investigated.

An announcement from 4D Molecular Therapeutics ( ($FDMT) ) is now available. On November 6, 2025, 4D Molecular Therapeutics announced positive ...